Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing o...
Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with ne...
As real-world evidence assumes a growing role in oncology research, regulatory evaluation, and clinical decision-making, the quality of underlying data has...
The promise of precision oncology depends not only on scientific innovation but also on successful implementation in routine clinical practice. Drawing on ...
Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need without an established treat...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, introd...
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade eviden...
As precision medicine continues to reshape cancer care, ensuring equitable access to genomic testing remains a critical priority. New research presented at...
What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meet...
From advanced biologics and cell therapies to increasingly stringent regulatory expectations, today’s pharmaceutical manufacturing environments dem...
FUJIFILM Corporation announced that it has developed an innovative screening methodology for cyclic peptides exhibiting high affinity toward membrane pro...
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...
Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase...
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed ac...
© 2026 Biopharma Boardroom. All Rights Reserved.
